← 產業報告目錄

Polycystic Ovarian Syndrome (PCOS) Market Research Report by Drug Class (Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agents, Antidepressants, Anti-Obesity, and Others.), By Route of Administration (oral and parenteral), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-05-02頁數 198報告編號 MRFRPharma4834CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The global Polycystic Ovarian Syndrome market is projected to grow from USD 5,839.82 million in 2025 to USD 10,130.72 million by 2035, registering a CAGR of 5.61% during the forecast period. The market growth is driven by rising awareness of PCOS, increasing diagnosis rates, and growing demand for advanced treatment options worldwide. Increasing Demand for Early and Accurate PCOS Diagnosis To diagnose polycystic ovarian syndrome (PCOS) accurately and early, which is one of the most important prerequisites for successful treatment, has already become one of the key factors why advanced ultrasound, including image-guided and Doppler ultrasound, is being adopted at such a breakneck pace globally. Newer diagnostic techniques like 3D imaging and Doppler-based assessments that allow clear visualization of ovarian morphology are being used to improve cancer diagnosis, clinical confidence, and patient management outcomes. Segmentations Insights By Drug Class • Oral Contraceptives – Widely prescribed for hormonal cycle regulation. • Antiandrogens – Help reduce excess androgen-related symptoms. • Insulin Sensitizing Agents – Improve insulin resistance among PCOS patients. • Antidepressants – Support mental health and emotional stability. • Anti-Obesity – Assist in effective long-term weight management. • Others – Include supportive and combination therapeutic treatments. By Route of Administration • Oral – Preferred due to convenience and easy usage. • Parenteral – Used for targeted and faster drug delivery. By Distribution Channel • Hospital Pharmacies – Ensure access to prescribed specialty medications. • Retail Pharmacies – Provide convenient availability of PCOS treatments. • Online Pharmacies – Growing rapidly with digital healthcare adoption. North America dominates the world Polycystic Ovarian Syndrome market due to advanced healthcare infrastructure, strong awareness, and favorable reimbursement policies, while Europe holds on to the steady growth through increased treatment accessibility and government-partnered initiatives. Asia Pacific is setting up to be the fastest-growing region as it is supported by rise in urbanization, increasing diagnosis rates, and expanding healthcare investments. Expansion of Women’s Health Portfolio In February 2022, Organon purchased the rights of contraceptive products only from Bayer AG in China including Hong Kong and Macau areas. Also, signing a strategic agreement for Vietnam. Through these actions, the company has significantly enhanced its women's health product line, increased its presence in Asia, and facilitated better regional access to contraceptive products. Rising Adoption of Point-of-Care Diagnostic Solutions Presently, the spreading use of Point-of-Care (POC) testing is providing a lucrative strategic opening for the global Polycystic Ovarian Syndrome market since it results in a quicker and easier diagnosis. Portable hormone-testing devices and rapid screening methods are not only increasing early detection rates but are also lessening reliance on centralized laboratory facilities. Key Report Attributes • Market Size 2025: USD 5 ,839.82 Million • Market Size 2035: USD 10,130.72 Million • CAGR (2025-2035): 5.61% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Drug Class: Oral Contraceptives - 5.78%, Antiandrogens - 4.51%. • By Route of Administration: Oral - 5.74%, Parenteral - 4.10%. • By Distribution Channel: Hospital pharmacies - 5.85%, Retail pharmacies - 4.64%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ........................................... 21 1.1 Overview .......................... 21 1.2 MARKET ATTRACTIVENESS ANALYSIS ......................... 22 1.3 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS ........ 23 1.4 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION ........................... 24 1.5 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL ................................. 25 1.6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION ................ 26 2 MARKET INTRODUCTION ....................................... 28 2.1 DEFINITION ...................... 28 2.2 SCOPE OF THE STUDY ...... 28 2.3 Research Objective ........... 28 2.4 MARKET STRUCTURE ........ 29 3 RESEARCH METHODOLOGY ................................. 30 3.1 Overview .......................... 30 3.2 DATA flow ........................ 32 3.2.1 DATA MINING PROCESS ...................................... 32 3.3 Purchased Database: ........ 33 3.4 Secondary Sources: .......... 34 3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 35 3.5 Primary Research: ............ 36 3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 37 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 38 3.6 Approaches for market size estimation: ........................ 39 3.6.1 REVENUE ANALYSIS APPROACH .......................... 39 3.7 Data forecasting ............... 39 3.7.1 DATA FORECASTING TYPE ................................... 40 3.8 Data modeling .................. 41 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 41 3.8.2 DATA MODELING: ..... 42 3.9 Teams and Analyst Contribution ................................... 44 4 MARKET DYNAMICS ............................................... 46 4.1 INTRODUCTION ................ 46 4.2 Drivers ............................. 47 4.2.1 RISING PREVALENCE OF INSULIN RESISTANCE & METABOLIC COMORBIDITIES ........................................... 47 4.2.2 IMPROVED ULTRASOUND TECHNOLOGY .............. 47 4.2.3 THE "INOSITOL" BOOM ........................................ 48 4.2.4 EXPANDING THERAPEUTIC SCOPE BEYOND REPRODUCTIVE SYMPTOMS ......... 48 4.3 Restraints ........................ 49 4.3.1 THE "THIN PCOS" PARADOX ................................ 49 4.3.2 LACK OF STANDARDIZED, CURATIVE TREATMENT ........................................... 50 4.3.3 HIGH ATTRITION IN CLINICAL TRIALS .................. 50 4.4 Opportunities ................... 51 4.4.1 TELEHEALTH SPECIALIZATION ............................ 51 4.4.2 POINT-OF-CARE (POC) TESTING ........................... 52 5 MARKET FACTOR ANALYSIS ................................. 53 5.1 Regulatory Environment & Compliance .......................... 53 5.2 Technological Trends & Innovation ............................... 54 5.3 Patient Demographics & Disease Burdens ..................... 55 5.4 Pricing Analysis & Reimbursement Dynamics ................ 56 5.4.1 PRICING ANALYSIS .............................................. 56 5.4.1.1 NORTH AMERICA ..... 56 5.4.1.2 EUROPE ................. 56 5.4.1.3 ASIA PACIFIC ......... 56 5.4.1.4 LATIN AMERICA ...... 56 5.4.1.5 MIDDLE EAST & AFRICA ....................................... 57 5.4.2 REIMBURSEMENT DYNAMICS .............................. 57 5.5 Market Entry & Exit Barriers .......................................... 58 5.5.1 BARRIERS TO ENTRY ........................................... 58 5.5.2 BARRIERS TO EXIT ............................................... 58 5.6 Partnerships & Collaborations ...................................... 59 5.7 Consumer & Healthcare Provider Preferences ............... 60 5.7.1 CONSUMER PREFERENCES .................................. 60 5.7.2 HEALTHCARE PROVIDER PREFERENCES ............... 60 5.8 PESTLE ANALYSIS ............ 60 5.8.1 POLITICAL FACTORS ........................................... 60 5.8.2 ECONOMIC FACTORS .......................................... 60 5.8.3 SOCIAL FACTORS ..... 61 5.8.4 TECHNOLOGICAL FACTORS ................................. 61 5.8.5 LEGAL FACTORS ...... 61 5.8.6 ENVIRONMENTAL FACTORS ................................ 61 5.9 Porter's Five Forces Model ........................................... 62 5.9.1 THREAT OF NEW ENTRANTS ................................ 63 5.9.2 BARGAINING POWER OF SUPPLIERS .................... 63 5.9.3 BARGAINING POWER OF BUYERS ......................... 63 5.9.4 THREAT OF SUBSTITUTES ................................... 63 5.9.5 INTENSITY OF RIVALRY ....................................... 63 5.10 Product Pipeline Analysis ............................................. 64 5.11 Case Study Analysis ......... 65 5.12 Investment & Funding Scenarios ................................... 66 5.13 Post-Market Surveillance & Safety Data ........................ 67 5.14 disease overview .............. 68 5.15 diagnosis ......................... 69 5.16 CURRENT TREATMENT ..... 70 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS .............................. 72 6.1 Overview .......................... 72 7 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION ... 76 7.1 Overview .......................... 76 8 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL ......... 78 8.1 Overview .......................... 78 9 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION ....................................... 81 9.1 Overview .......................... 81 9.2 North America .................. 83 9.2.1 US ........................... 88 9.2.2 CANADA .................. 90 9.3 europe ............................. 92 9.3.1 GERMANY ................ 97 9.3.2 UK ........................... 99 9.3.3 FRANCE ................... 101 9.3.4 NETHERLANDS ......... 103 9.3.5 ITALY ....................... 105 9.3.6 SPAIN ...................... 107 9.3.7 REST OF EUROPE ...... 109 9.4 ASIA-PACIFIC ................... 111 9.4.1 CHINA ...................... 116 9.4.2 INDIA ....................... 118 9.4.3 JAPAN ..................... 120 9.4.4 SOUTH KOREA .......... 122 9.4.5 MALAYSIA ............... 124 9.4.6 THAILAND ................ 126 9.4.7 INDONESIA .............. 128 9.4.8 REST OF APAC ......... 130 9.5 LATIN america ................. 132 9.5.1 BRAZIL ..................... 137 9.5.2 MEXICO ................... 139 9.5.3 ARGENTINA ............. 141 9.5.4 REST OF LATIN AMERICA ..................................... 143 9.6 iddle east & africa ............. 145 9.6.1 GCC COUNTRIES ...... 150 9.6.2 SOUTH AFRICA ......... 152 9.6.3 REST OF MEA ........... 154 10 COMPETITIVE LANDSCAPE ................................... 157 10.1 Introduction ..................... 157 10.2 Market Share Analysis, 2025 ........................................ 157 10.3 competitor dashboard ....... 158 10.4 Public Players Stock Summary ..................................... 159 10.5 Comparative Analysis: Key Players Financial ................. 159 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............. 160 10.6.1 ACQUISITION ........... 160 10.6.2 STRATEGIC ALLIANCE ......................................... 160 11 COMPANY PROFILES ............................................. 161 11.1 Bayer AG .......................... 161 11.1.1 COMPANY OVERVIEW .......................................... 161 11.1.2 FINANCIAL OVERVIEW ......................................... 162 11.1.3 PRODUCTS OFFERED ........................................... 163 11.1.4 KEY DEVELOPMENTS .......................................... 163 11.1.5 SWOT ANALYSIS ...... 164 11.1.6 KEY STRATEGIES ...... 165 11.2 Pfizer Inc. ........................ 166 11.2.1 COMPANY OVERVIEW .......................................... 166 11.2.2 FINANCIAL OVERVIEW ......................................... 167 11.2.3 PRODUCTS OFFERED ........................................... 168 11.2.4 KEY DEVELOPMENTS .......................................... 168 11.2.5 SWOT ANALYSIS ...... 168 11.2.6 KEY STRATEGIES ...... 169 11.3 Sanofi .............................. 170 11.3.1 COMPANY OVERVIEW .......................................... 170 11.3.2 FINANCIAL OVERVIEW ......................................... 171 11.3.3 PRODUCTS OFFERED ........................................... 172 11.3.4 KEY DEVELOPMENTS .......................................... 172 11.3.5 SWOT ANALYSIS ...... 172 11.3.6 KEY STRATEGY ......... 173 11.4 AstraZeneca ..................... 174 11.4.1 COMPANY OVERVIEW .......................................... 174 11.4.2 FINANCIAL OVERVIEW ......................................... 175 11.4.4 KEY DEVELOPMENTS .......................................... 176 11.4.5 KEY STRATEGIES ...... 176 11.5 Ferring Pharmaceuticals .............................................. 177 11.5.1 COMPANY OVERVIEW .......................................... 177 11.5.2 FINANCIAL OVERVIEW ......................................... 178 11.5.3 PRODUCTS OFFERED ........................................... 179 11.5.4 KEY DEVELOPMENTS .......................................... 179 11.5.5 KEY STRATEGIES ...... 179 11.6 Theramex ......................... 180 11.6.1 COMPANY OVERVIEW .......................................... 180 11.6.2 FINANCIAL OVERVIEW ......................................... 180 11.6.3 PRODUCTS OFFERED ........................................... 181 11.6.4 KEY DEVELOPMENTS .......................................... 181 11.6.5 KEY STRATEGIES ...... 181 11.7 Teva Pharmaceutical Industries Ltd. ............................. 182 11.7.1 COMPANY OVERVIEW .......................................... 182 11.7.2 FINANCIAL OVERVIEW ......................................... 183 11.7.3 DEVELOPMENTS ...... 184 11.7.4 KEY DEVELOPMENTS .......................................... 184 11.7.5 SWOT ANALYSIS ...... 184 11.7.6 KEY STRATEGIES ...... 185 11.8 Merck KGgA ..................... 186 11.8.1 COMPANY OVERVIEW .......................................... 186 11.8.2 FINANCIAL OVERVIEW ......................................... 187 11.8.3 DEVELOPMENTS ...... 188 11.8.4 KEY DEVELOPMENTS .......................................... 188 11.8.5 SWOT ANALYSIS ...... 188 11.8.6 KEY STRATEGIES ...... 189 11.9 Organon ........................... 190 11.9.1 COMPANY OVERVIEW .......................................... 190 11.9.2 FINANCIAL OVERVIEW ......................................... 191 11.9.3 DEVELOPMENTS ...... 192 11.9.4 KEY DEVELOPMENTS .......................................... 192 11.9.5 KEY STRATEGIES ...... 192 11.10 Novo Nordisk A/S ............. 193 11.10.1 COMPANY OVERVIEW .......................................... 193 11.10.2 FINANCIAL OVERVIEW ......................................... 194 11.10.3 DEVELOPMENTS ...... 194 11.10.4 KEY DEVELOPMENTS .......................................... 195 11.10.5 KEY STRATEGIES ...... 195 12 DATA CITATIONS .......... 196
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 43 TABLE 2 PRODUCT PIPELINE 64 TABLE 3 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 73 TABLE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 74 TABLE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 74 TABLE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 77 TABLE 7 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 79 TABLE 8 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION, 2019-2035 (USD MILLION) 82 TABLE 9 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 84 TABLE 10 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 85 TABLE 11 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 86 TABLE 12 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 86 TABLE 13 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 87 TABLE 14 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 87 TABLE 15 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 88 TABLE 16 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 88 TABLE 17 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 89 TABLE 18 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 89 TABLE 19 US POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 89 TABLE 20 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 90 TABLE 21 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 90 TABLE 22 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 91 TABLE 23 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 91 TABLE 24 CANADA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 91 TABLE 25 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 93 TABLE 26 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 94 TABLE 27 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 95 TABLE 28 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 95 TABLE 29 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 95 TABLE 30 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 96 TABLE 31 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 97 TABLE 32 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 97 TABLE 33 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 98 TABLE 34 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 98 TABLE 35 GERMANY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 98 TABLE 36 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 99 TABLE 37 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 99 TABLE 38 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 100 TABLE 39 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 100 TABLE 40 UK POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 100 TABLE 41 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 101 TABLE 42 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 101 TABLE 43 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 102 TABLE 44 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 102 TABLE 45 FRANCE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 102 TABLE 46 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 103 TABLE 47 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 103 TABLE 48 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 104 TABLE 49 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 104 TABLE 50 NETHERLANDS POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 104 TABLE 51 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 105 TABLE 52 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 105 TABLE 53 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 106 TABLE 54 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 106 TABLE 55 ITALY POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 106 TABLE 56 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 107 TABLE 57 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 107 TABLE 58 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 108 TABLE 59 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 108 TABLE 60 SPAIN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 108 TABLE 61 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 109 TABLE 62 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 109 TABLE 63 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 110 TABLE 64 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 110 TABLE 65 REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 110 TABLE 66 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 112 TABLE 67 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 113 TABLE 68 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 114 TABLE 69 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 114 TABLE 70 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 114 TABLE 71 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 115 TABLE 72 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 116 TABLE 73 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 116 TABLE 74 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 117 TABLE 75 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 117 TABLE 76 CHINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 117 TABLE 77 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 118 TABLE 78 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 118 TABLE 79 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 119 TABLE 80 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 119 TABLE 81 INDIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 119 TABLE 82 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 120 TABLE 83 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 120 TABLE 84 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 121 TABLE 85 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 121 TABLE 86 JAPAN POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 121 TABLE 87 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 122 TABLE 88 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 122 TABLE 89 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 123 TABLE 90 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 123 TABLE 91 SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 123 TABLE 92 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 124 TABLE 93 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 124 TABLE 94 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 125 TABLE 95 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 125 TABLE 96 MALAYSIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 125 TABLE 97 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 126 TABLE 98 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 126 TABLE 99 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 127 TABLE 100 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 127 TABLE 101 THAILAND POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 127 TABLE 102 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 128 TABLE 103 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 128 TABLE 104 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 129 TABLE 105 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 129 TABLE 106 INDONESIA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 129 TABLE 107 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 130 TABLE 108 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 130 TABLE 109 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 131 TABLE 110 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 131 TABLE 111 REST OF APAC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 131 TABLE 112 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 133 TABLE 113 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 134 TABLE 114 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 135 TABLE 115 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 135 TABLE 116 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 136 TABLE 117 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 136 TABLE 118 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 137 TABLE 119 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 137 TABLE 120 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 138 TABLE 121 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 138 TABLE 122 BRAZIL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 138 TABLE 123 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 139 TABLE 124 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 139 TABLE 125 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 140 TABLE 126 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 140 TABLE 127 MEXICO POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 140 TABLE 128 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 141 TABLE 129 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 141 TABLE 130 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 142 TABLE 131 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 142 TABLE 132 ARGENTINA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 142 TABLE 133 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 143 TABLE 134 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 143 TABLE 135 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 144 TABLE 136 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 144 TABLE 137 REST OF LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 144 TABLE 138 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 147 TABLE 139 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 148 TABLE 140 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 148 TABLE 141 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 149 TABLE 142 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 149 TABLE 143 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 149 TABLE 144 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 150 TABLE 145 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 150 TABLE 146 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 151 TABLE 147 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 151 TABLE 148 GCC COUNTRIES POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 151 TABLE 149 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 152 TABLE 150 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 152 TABLE 151 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 153 TABLE 152 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 153 TABLE 153 SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 153 TABLE 154 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 154 TABLE 155 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY INSULIN SENSITIZING AGENTS, 2019-2035 (USD MILLION) 154 TABLE 156 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ANTI-OBESITY, 2019-2035 (USD MILLION) 155 TABLE 157 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 155 TABLE 158 REST OF MEA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 155 TABLE 159 ACQUISITION 160 TABLE 160 STRATEGIC ALLIANCE 160 TABLE 161 BAYER AG: PRODUCT OFFERED 163 TABLE 162 BAYER AG: KEY DEVELOPMENTS 163 TABLE 163 PFIZER INC.: PRODUCTS OFFERED 168 TABLE 164 SANOFI.: PRODUCTS OFFERED 172 TABLE 166 FERRING PHARMACEUTICALS: PRODUCTS OFFERED 179 TABLE 167 THERAMEX: PRODUCTS OFFERED 181 TABLE 168 THERAMEX: KEY DEVELOPMENTS 181 TABLE 169 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 184 TABLE 170 MERCK KGAA: PRODUCTS OFFERED 188 TABLE 171 ORGANON: PRODUCTS OFFERED 192 TABLE 172 ORGANON: KEY DEVELOPMENT 192 TABLE 173 NOVO NORDISK A/S: PRODUCTS OFFERED 194 LIST OF FIGURES FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, 2025 22 FIGURE 2 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET ANALYSIS, BY DRUG CLASS, 2025 (USD MILLION AND %) 23 FIGURE 3 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION, 2025 (USD MILLION AND %) 24 FIGURE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2025 (USD MILLION AND %) 25 FIGURE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET ANALYSIS, BY REGION, 2025 (USD MILLION AND %) 26 FIGURE 1 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET: STRUCTURE 29 FIGURE 2 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 46 FIGURE 3 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET DRIVER: IMPACT ANALYSIS 49 FIGURE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET RESTRAINT: IMPACT ANALYSIS 51 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL POLYCYSTIC OVARY SYNDROME (PCOS) MARKET 62 FIGURE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, DRUG CLASS SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 72 FIGURE 7 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DRUG CLASS, 2025 & 2035 (USD MILLION) 73 FIGURE 8 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY DRUG CLASS, 2025 75 FIGURE 9 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 76 FIGURE 10 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY ROUTE OF ADMINISTRATION, 2025 & 2035 (USD MILLION) 76 FIGURE 11 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2025 77 FIGURE 12 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 78 FIGURE 13 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY DISRIBUTION CHANNEL, 2025 & 2035 (USD MILLION) 79 FIGURE 14 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025 80 FIGURE 15 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY REGION, 2025 & 2035 (USD MILLION) 81 FIGURE 16 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY REGION, 2025 82 FIGURE 17 NORTH AMERICA MARKET ANALYSIS: POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, 2019-2035 (USD MILLION) 83 FIGURE 18 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 84 FIGURE 19 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY COUNTRY, 2025 85 FIGURE 20 EUROPE MARKET ANALYSIS: POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, 2019-2035 (USD MILLION) 92 FIGURE 21 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 93 FIGURE 22 EUROPE POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY COUNTRY, 2025 94 FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS: POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, 2019-2035 (USD MILLION) 111 FIGURE 24 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 112 FIGURE 25 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY COUNTRY, 2025 113 FIGURE 26 LATIN AMERICA MARKET ANALYSIS: POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, 2019-2035 (USD MILLION) 132 FIGURE 27 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 133 FIGURE 28 LATIN AMERICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY COUNTRY, 2025 134 FIGURE 29 MIDDLE EAST & AFRICA MARKET ANALYSIS: POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, 2019-2035 (USD MILLION) 145 FIGURE 30 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 146 FIGURE 31 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET SHARE (%), BY COUNTRY, 2025 147 FIGURE 32 GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 157 FIGURE 33 COMPETITOR DASHBOARD: GLOBAL POLYCYSTIC OVARIAN SYNDROME (PCOS) MARKET 158 FIGURE 34 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 162 FIGURE 35 BAYER AG : SWOT ANALYSIS 164 FIGURE 36 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 167 FIGURE 37 PFIZER INC.: SWOT ANALYSIS 168 FIGURE 38 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 171 FIGURE 39 SANOFI: SWOT ANALYSIS 172 FIGURE 40 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 175 FIGURE 41 FERRING PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 178 FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 183 FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 184 FIGURE 44 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 187 FIGURE 45 MERCK KGGA: SWOT ANALYSIS 188 FIGURE 46 ORGANON: FINANCIAL OVERVIEW SNAPSHOT 191 FIGURE 47 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 194

提及公司

TheramexTeva Pharmaceutical Industries Ltd.Merck KGaAOrganonNovo Nordisk A/SBayer AGPfizer Inc.SanofiAstraZenecaFerring Pharmaceuticals

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們